Parkinson Association of Alabamahttp://www.parkinsonalabama.com Improving the quality of life for Parkinson patients, their caregivers, and families in the State of AlabamaFri, 22 Feb 2019 16:30:31 +0000en-UShourly1https://wordpress.org/?v=5.0.3Role of Environmental Factors in Parkinson’s Development Investigated in Review Studyhttp://www.parkinsonalabama.com/role-of-environmental-factors-in-parkinsons-development-investigated-in-review-study/ http://www.parkinsonalabama.com/role-of-environmental-factors-in-parkinsons-development-investigated-in-review-study/#respondMon, 04 Feb 2019 14:41:00 +0000http://www.parkinsonalabama.com/?p=3731395The hallmark presence of Lewy bodies in the pathway related to sense of smell and in the gut years before a Parkinson’s diagnosis, as well as the potential cumulative impact of different triggers, may help researchers understand the environmental factors that contribute to the development of the disease, according to a review study. The study, […]

The post Role of Environmental Factors in Parkinson’s Development Investigated in Review Study appeared first on Parkinson Association of Alabama.

]]>
environmental causes

The hallmark presence of Lewy bodies in the pathway related to sense of smell and in the gut years before a Parkinson’s diagnosis, as well as the potential cumulative impact of different triggers, may help researchers understand the environmental factors that contribute to the development of the disease, according to a review study.

The study, “The Search for Environmental Causes of Parkinson’s Disease: Moving Forward,” appeared in the Journal of Parkinson’s Disease.

Environmental factors contribute at least partially to late-onset sporadic Parkinson’s disease. Because neurodegenerative changes are too advanced to be stopped or reversed by the time a diagnosis is reached, understanding modifiable risk factors that can help to identify the disease and allow for an early intervention may lead to more successful treatment of Parkinson’s, the neurological disease with the fastest-growing prevalence.

“The greatest risk factors for [Parkinson’s] are likely environmental and not genetic,” Honglei Chen, MD, PhD, from Michigan State University, and Beate Ritz, MD, PhD, from the University of California Los Angeles, said in a press release. “Yet we know relatively little about environmental causes or triggers. Identifying these and defining ways to reduce their impact will be great research challenges for the coming two decades.”

Environmental factors may trigger Parkinson’s or modify its progression during the prodromal (early) stage, in which early symptoms or signs are present, but clinical diagnosis is not yet possible. Among the reported factors, smoking, coffee, exercise, plasma urate, and use of ibuprofen have been linked to a lower risk of Parkinson’s, while pesticide exposure and traumatic brain injury have been associated with a greater risk.

Apart from two pesticides known as rotenone and paraquat, researchers have had difficulties in providing evidence that other risk factors can cause the disease. Reverse causation — meaning that Parkinson’s changes lifestyle and behavior before a clinical diagnosis rather than the other way around — has been proposed as an explanation for the link between these environmental triggers and Parkinson’s in its early stages.

“This prodromal stage is of major interest for prevention efforts,” the researchers said in the release, adding that the discovery of Lewy bodies — protein aggregates mainly composed of alpha-synuclein that are characteristic of Parkinson’s — in the olfactory pathway and the digestive tract made targeting factors that enter the body via the nose or gut “even more important.”

The Braak hypothesis presents a potential explanation for environmental contributions in Parkinson’s prodromal development. It suggests that Lewy pathology starts in the brain’s olfactory bulb — an area of the brain involved in the sense of smell — or in enteric (gut) nerves (nerve cells that control the function of the gastrointestinal tract) years, if not decades, before reaching the substantia nigra — an area of the brain key in the control of movement that shows progressive loss of dopamine-producing neurons in Parkinson’s disease.

Findings such as a reduced sense of smell and constipation years before a Parkinson’s diagnosis have supported the Braak hypothesis. Pesticides and other environmental toxins such as air pollutants, of which there is growing evidence of harmful effects on cognitive function, organic solvents, and meats cooked at high temperatures may lead to Parkinson’s through these pathways, although a proinflammatory gut microbiome — the community of bacteria, viruses and fungi that lives in the gut — has also been proposed as a potential starting point. Certain genetic factors may also interact with these environmental causes to boost the risk for the disease.

Besides the Braak hypothesis, the scientists also discussed reported epigenetic differences — alterations in gene function but not in the DNA sequence itself — in the blood and saliva of people with Parkinson’s as well as the importance of lifelong exposure to environmental triggers.

The exposome, which refers to all environmental exposures over a lifetime, suggests that multiple environmental stimuli combine to increase the risk of Parkinson’s. This has been shown with traumatic brain injury and paraquat exposure, and with smoking combined with factors such as caffeine intake and physical activity.

“We are at an exciting moment to unveil environmental contributions to [Parkinson’s] development and progression by taking a life-course approach, and utilizing novel tools to assess environmental exposures,” the researchers said.

While they caution that the long duration of the prodromal stage complicates understanding the extent to which environmental factors contribute to Parkinson’s, the investigators “nevertheless believe it will be possible to assess long-term exposures through large-scale environmental monitoring and by using novel biomarkers that reflect the exposome.”

Both the Braak hypothesis and the exposome concept provide “a theoretical framework for scientists to design future studies to decipher the environmental causes of [Parkinson’s] and develop early interventions to halt the progression to the characteristic motor dysfunction in [Parkinson’s],” they concluded.

The post Role of Environmental Factors in Parkinson’s Development Investigated in Review Study appeared first on Parkinson’s News Today.

The post Role of Environmental Factors in Parkinson’s Development Investigated in Review Study appeared first on Parkinson Association of Alabama.

]]>
http://www.parkinsonalabama.com/role-of-environmental-factors-in-parkinsons-development-investigated-in-review-study/feed/0
Parkinson Voice Project Going Global with Speech Therapy Grant Programhttp://www.parkinsonalabama.com/parkinson-voice-project-going-global-with-speech-therapy-grant-program/ http://www.parkinsonalabama.com/parkinson-voice-project-going-global-with-speech-therapy-grant-program/#respondThu, 31 Jan 2019 13:00:00 +0000http://www.parkinsonalabama.com/?p=3731351This year, Parkinson Voice Project (PVP) is broadening its SPEAK OUT! & LOUD Crowd Grant Program to include support for international speech therapy clinics. The expanded grant program is intended to help Parkinson’s disease patients around the world gain access to quality speech treatment to maintain their speaking abilities and minimize the threat of swallowing problems. In addition […]

The post Parkinson Voice Project Going Global with Speech Therapy Grant Program appeared first on Parkinson Association of Alabama.

]]>
speech therapy grants

This year, Parkinson Voice Project (PVP) is broadening its SPEAK OUT! & LOUD Crowd Grant Program to include support for international speech therapy clinics.

The expanded grant program is intended to help Parkinson’s disease patients around the world gain access to quality speech treatment to maintain their speaking abilities and minimize the threat of swallowing problems.

In addition to facilities in the U.S., grant recipients this year will include five clinics based outside the country. Applications are now being accepted and are due March 1. Recipients will be announced in April during Parkinson’s Awareness Month. Go here for full eligibility requirements, and visit this site to apply.

Nonprofit organizations, universities/graduate students, and hospitals who would like to bring PVP’s speech therapy program to their communities are encouraged to apply. Applicants must have the physical space and clinical staff necessary to provide both individual and group speech therapy. Last year’s winners may reapply for continued support of their programs.

For international applicants, awards are open to any clinic that can use English or Spanish-based therapy materials.

To achieve its mission of making speech treatment widely accessible, PVP recognized a need to support speech language pathologists. These professionals, according to the organization, get low insurance reimbursement for services, and also often have trouble securing funding from employers for specialized training and supplies. The grants are designed to provide pathologists with the knowledge and tools needed to help the Parkinson’s community.

The grant program, which honors the late Parkinson’s speech expert Daniel R. Boone, PhD, was launched last year with 92 grants awarded to speech therapy clinics nationwide. Of them, 34 were university-based clinics.

More than 900 speech language pathologists and graduate students received training in SPEAK OUT! and LOUD Crowd therapy protocols, plus speech therapy supplies, funding support for their organizations, and a trip to PVP’s clinic in Dallas-Fort Worth for hands-on training.

“Our grant program was a huge success in 2018,” said PVP CEO Samantha Elandary, in a press release. “Our goal is to make quality speech treatment available to those living with Parkinson’s around the globe.”

According to Elandary, Parkinson’s affects more than 1 million U.S. residents, and up to 10 million people worldwide. Some 89 percent of patients are likely to develop speech disorders that can lead to swallowing difficulties.

Combining speech, voice, and cognitive exercises, SPEAK OUT! addresses the motor speech issues related to Parkinson’s. LOUD Crowd is a voice maintenance program consisting of speech therapy groups and a singing segment to foster voice strength retention.

Using the two-part trademarked speech therapy program, the patient and a speech language pathologist tackle a series of speech, voice, and cognitive exercises outlined in a specialized workbook. Stressing “speaking with intent,” the program switches speech from an automatic function to a deliberate act. Because speech muscles are also used for swallowing, the benefits of the therapy are twofold.

Grant funding will come from the more than $2 million PVP raised over the past holiday season.

Through intensive speech therapy, follow-up support, research, education and community awareness, the nonprofit aims to preserve the voices of those with Parkinson’s and related disorders. To date, it has trained more than 1,300 speech language pathologists nationwide. Internationally, it has trained therapists in eight countries.

Among other offerings, the organization also hosts an educational lecture series. Earlier this month, Susan Imke, a certified gerontological nurse practitioner who focuses on families living with Parkinson’s disease and other neurodegenerative disorders, discussed “Optimal Nutrition for Living Well with Parkinson’s.” The next presentation, “Packing Some ‘Punch’ Into Your Parkinson’s Exercise Routine,” will be Feb. 9.

The post Parkinson Voice Project Going Global with Speech Therapy Grant Program appeared first on Parkinson’s News Today.

The post Parkinson Voice Project Going Global with Speech Therapy Grant Program appeared first on Parkinson Association of Alabama.

]]>
http://www.parkinsonalabama.com/parkinson-voice-project-going-global-with-speech-therapy-grant-program/feed/0
My PD Frustration Consists of More Than Only Symptoms and Treatmentshttp://www.parkinsonalabama.com/my-pd-frustration-consists-of-more-than-only-symptoms-and-treatments/ http://www.parkinsonalabama.com/my-pd-frustration-consists-of-more-than-only-symptoms-and-treatments/#respondTue, 29 Jan 2019 15:02:00 +0000http://www.parkinsonalabama.com/?p=3731330    by Jean Mellano “You don’t have to be positive all the time. It’s perfectly okay to feel sad, angry, annoyed, frustrated, scared and anxious. Having feelings doesn’t make you a ‘negative person.’ It makes you human.” –Lori Deschene As many people with Parkinson’s will attest, both Parkinson’s disease (PD) symptoms and finding the right […]

The post My PD Frustration Consists of More Than Only Symptoms and Treatments appeared first on Parkinson Association of Alabama.

]]>
 

 

by Jean Mellano

You don’t have to be positive all the time. It’s perfectly okay to feel sad, angry, annoyed, frustrated, scared and anxious. Having feelings doesn’t make you a ‘negative person.’ It makes you human.” –Lori Deschene

As many people with Parkinson’s will attest, both Parkinson’s disease (PD) symptoms and finding the right treatment to alleviate them can be extremely frustrating.

The perception

Just as frustrating for me is that everyone thinks I am fine. Since I have no tremors, there are no obvious symptoms. Most well-meaning, healthy people either tell me I look great or that they have the same issues as me — cognitive decline, balance, poor fine motor skills, slowness of movement, and fatigue.

The truth

I struggle to maintain balance and must consciously avoid walking into furniture. My body, especially on the left side, does not always listen to me when I tell it to do something. Trying to maintain focus to do this is draining in itself. I also feel weak inside and I am always extremely fatigued. It is an exhaustion that no amount of sleep or rest can diminish.

A glimpse into my frustration

To help my fine motor skills, I have taken up ukulele lessons. I never played any instrument in my life, so I have no muscle memory to call on. The left hand and fingers play a huge role in learning how to use this instrument.

Recently, I had a meltdown in one of my lessons. My left fingers were not listening to me while trying to play some chords. The instructor was very patient, but I don’t think he understood the extent of my struggles. I was trying to play a G chord, which requires positioning three fingers from my left hand on various frets. These fingers would not cooperate and they just froze. With all the energy I expended trying to get my fingers positioned, I worked up a sweat.

Finally, so full of despair and frustration over what I have lost, I just broke down in tears. I can no longer control my body.

Empathy

The frustration continues on many fronts for me: the symptoms themselves, trying to find something to help treat my symptoms, and well-intentioned people not comprehending what I struggle with daily. Many years before I was affected by this disease, a friend of mine was diagnosed with PD. I could never understand why it was so hard for her to put on a seat belt.

Now I know.

I have a form of Parkinson’s disease, which I don’t like. My legs don’t move when my brain tells them to. It’s very frustrating.” –George H. W. Bush

The post My PD Frustration Consists of More Than Only Symptoms and Treatments appeared first on Parkinson’s News Today.

The post My PD Frustration Consists of More Than Only Symptoms and Treatments appeared first on Parkinson Association of Alabama.

]]>
http://www.parkinsonalabama.com/my-pd-frustration-consists-of-more-than-only-symptoms-and-treatments/feed/0
New Parkinson’s Drug Comes to Market after Early Investment from The Michael J. Fox Foundationhttp://www.parkinsonalabama.com/new-parkinsons-drug-comes-to-market-after-early-investment-from-the-michael-j-fox-foundation/ http://www.parkinsonalabama.com/new-parkinsons-drug-comes-to-market-after-early-investment-from-the-michael-j-fox-foundation/#respondFri, 11 Jan 2019 15:44:33 +0000http://www.parkinsonalabama.com/?p=3730886People with Parkinson’s have a new treatment option due in part to funding from The Michael J. Fox Foundation (MJFF). On December 21, 2018, the U.S. Food and Drug Administration approved Inbrija, an inhaled levodopa powder, for “off” episodes, when Parkinson’s symptoms are not well controlled with oral medication. MJFF supported early clinical trials of […]

The post New Parkinson’s Drug Comes to Market after Early Investment from The Michael J. Fox Foundation appeared first on Parkinson Association of Alabama.

]]>
People with Parkinson’s have a new treatment option due in part to funding from The Michael J. Fox Foundation (MJFF). On December 21, 2018, the U.S. Food and Drug Administration approved Inbrija, an inhaled levodopa powder, for “off” episodes, when Parkinson’s symptoms are not well controlled with oral medication. MJFF supported early clinical trials of the treatment, and this is the first regulatory approval of a Parkinson’s therapy directly funded by our Foundation.

“Our strategy of funding high-risk, high-reward projects with a focus on patient impact has paid off,” said MJFF CEO Todd Sherer, PhD. “Today people with Parkinson’s have a new option to manage life with the disease. Because of our Foundation’s investments, many more treatments to manage symptoms and to stop progression are moving closer to pharmacy shelves and patient hands.”

MJFF partially funded Phase I and II trials of Inbrija by biotechnology company Civitas Therapeutics in 2011and 2013 with two grants totaling $1.3 million. Acorda Therapeutics, Inc. acquired Civitas in 2014 and continued the development of Inbrija.

De-risking Investments for Larger Partners

We provide early-stage therapeutic projects with the capital needed to advance. Grantees use our funding to build evidence of safety and efficacy, which can attract larger partners with resources for later-stage testing, regulatory processes and commercialization. Our Foundation directs donor-raised funds to the areas of most pressing patient need: from better symptom management to treatments to slow, stop or even prevent Parkinson’s progression.

“The way The Michael J. Fox Foundation does it is really best in class. The lack of bureaucracy and obstacles encourages emerging companies to seek funding and engagement and ultimately advance their projects,” said Glenn Batchelder, co-founder and former CEO of Civitas Therapeutics and member of the MJFF Board of Directors.

This “de-risking” model has advanced dozens of Parkinson’s therapies. Treatments with potential to slow or stop the disease are marching through clinical trials with new partners after early MJFF funding. Therapies targeting individual symptoms are experiencing similar momentum, and the Food and Drug Administration is currently reviewing another MJFF-funded Parkinson’s treatment for “off” episodes: APL-130277 from Sunovion Pharmaceuticals.

Other efforts from our Foundation speed these studies, as well. Educating the Parkinson’s community on “off” episodes through our communications channels helps potential trial volunteers recognize these fluctuations and seek new options. Our study matching tool Fox Trial Finder helped some participants connect directly with these trials, and we held a meeting with payers (e.g., Medicare/Medicaid and insurance companies) to discuss the impact of Parkinson’s symptoms, including “off” episodes. That knowledge may impact decisions on medication coverage.

New Option for Unmet Patient Need

The newly approved Inbrija, which Acorda expects to become available to patients in the first quarter of 2019, helps quickly alleviate symptoms of tremor, slowness and stiffness. With long-term oral levodopa use and advancing disease, these aspects of the disease can re-emerge between medication doses. These “off” episodes can greatly impact quality of life, bringing uncertainty to one’s days and limiting ability to complete daily tasks.

A 2014 MJFF survey of more than 3,000 people with Parkinson’s disease found that more than 60 percent of respondents were in an “off” state for two or more hours per day and nearly 50 percent said their “off” episodes caused them to avoid or stop activities.

Acorda Therapeutics CEO Ron Cohen notes, “It was clear thanks to the work of MJFF that ‘off’ episodes were a serious symptom for many Parkinson’s patients. Acorda committed to addressing this, and the FDA approval means patients will soon have a new treatment option.”

Acorda and The Michael J. Fox Foundation are collaborating on a number of projects, including a study of how patients, care partners and doctors discuss “off” episodes to identify gaps in communication and thereby optimum care.

This article first appeared on the Michael J Fox Foundation’s Foxfeed Blog

The post New Parkinson’s Drug Comes to Market after Early Investment from The Michael J. Fox Foundation appeared first on Parkinson Association of Alabama.

]]>
http://www.parkinsonalabama.com/new-parkinsons-drug-comes-to-market-after-early-investment-from-the-michael-j-fox-foundation/feed/0
Meditation and Parkinson’s Disease: Looking for Lightness of Beinghttp://www.parkinsonalabama.com/meditation-and-parkinsons-disease-looking-for-lightness-of-being/ http://www.parkinsonalabama.com/meditation-and-parkinsons-disease-looking-for-lightness-of-being/#respondFri, 11 Jan 2019 15:03:00 +0000http://www.parkinsonalabama.com/?p=3730873Living with Parkinson’s disease is a struggle against the loss of both motor and cognitive functions. One must invest effort into an action plan that reduces the impact of the disease — a rehab plan. This effort is daily (sometimes hourly) and can be exhausting. Living with PD is like carrying a large backpack of […]

The post Meditation and Parkinson’s Disease: Looking for Lightness of Being appeared first on Parkinson Association of Alabama.

]]>
meditation

Living with Parkinson’s disease is a struggle against the loss of both motor and cognitive functions. One must invest effort into an action plan that reduces the impact of the disease — a rehab plan. This effort is daily (sometimes hourly) and can be exhausting.

Living with PD is like carrying a large backpack of rocks. It is at times a crushing burden that can overwhelm. Balance needs to be established in my life so that the work I do in fighting the disease does not consume me. I must spend time looking for lightness of being to balance out the heavy PD burden. I do this through a regular practice of meditation.

There are many ways to practice meditation: sitting and listening to calming music, sitting and gazing at a fireplace, practicing tai chi, or exercising with rhythmic breathing. These practices seek to help one enter the quiet mind. It is within the quiet mind that one experiences lightness of being. Meditation helps relieve stress and focus attention — both of which are of benefit to those with PD. There are books providing instructions on how to do this, but none deal directly with PD.

Practicing meditation with PD presents some unique challenges. The meditation practice starts with calming the body, and this is the first obstacle PD complicates. Repetitive motor activities like cycling, tai chi, or gardening are helpful when combined with focused breathwork.

Focused breathwork is diaphragm breathing in which you focus your full attention on the breath. Guided meditation, either from a teacher, in person, or from a recording, can help with this process of shifting attention. This shifting of attention is the second obstacle PD complicates.

Once past the first two obstacles, you should feel a little more relaxed. This relaxed state is the path leading to the door into the quiet mind, but I am prevented from going down that path by a third obstacle.

This third obstacle is heightened emotions and difficulty in regulating them. I have written about how PD heightens the impulse signals to the brain. During the meditation process, the signal-to-noise ratio changes, meaning that as one practices quieting the mind, the noise goes down and the signals connected to emotion appear louder.

The quiet mind is a mental state that silences the noise of the world, the body, and the self while at the same time maintaining a sense of peace and safety. It is something I practiced for decades and then lost touch with over the last seven years while battling PD. As my life has become stable, I am now returning to the practice and finding it much more difficult. I feel like a novice struggling with all the obstacles I used to walk around with ease. This third obstacle does impede my looking for lightness of being.

As I have helped patients to find a place of peace and safety, together we would often experience loud emotions. These are emotions connected to things we feel (consciously or subconsciously) that need attention. They are like boulders in the path, looking like obstacles blocking the way forward to the quiet mind. But one can learn to walk around them.

Most of the folks I worked with would have several boulders to walk around and needed multiple sessions to learn how to walk around them. As I write this, I remember the tender patience I should offer to myself.

Once past the boulders of emotion, you then arrive at the doorstep of the quiet mind. PD has made looking for lightness of being much more difficult for me, but not impossible. I have memories, and recently have felt glimpses of peace and deep calmness.

Seeking lightness of being ties into my New Year’s resolution. For me to quiet down the old tapes (emotional boulders in the path), I need to have a new mental state to go to. I can’t just remove the tapes and leave a void, because that void will be quickly filled back in with the old mental habits. Looking for lightness of being will be a lifetime adventure.

What ways do you practice meditation, and how have you found it to be helpful?

***

Note: Parkinson’s News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Parkinson’s News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to Parkinson’s disease.

The post Meditation and Parkinson’s Disease: Looking for Lightness of Being appeared first on Parkinson’s News Today.

The post Meditation and Parkinson’s Disease: Looking for Lightness of Being appeared first on Parkinson Association of Alabama.

]]>
http://www.parkinsonalabama.com/meditation-and-parkinsons-disease-looking-for-lightness-of-being/feed/0
The Season of Givinghttp://www.parkinsonalabama.com/the-season-of-giving-2018/ http://www.parkinsonalabama.com/the-season-of-giving-2018/#respondMon, 10 Dec 2018 15:14:13 +0000http://www.parkinsonalabama.com/?p=3730485PAA is blessed to have an active, passionate, and growing support network of board members, volunteers, donors, sponsors, and thought leaders. It is because of this generous support – by people just like you – that PAA continues to fulfill and grow the promise of its mission to improve the lives of Parkinson’s patients, caregivers, […]

The post The Season of Giving appeared first on Parkinson Association of Alabama.

]]>

PAA is blessed to have an active, passionate, and growing support network of board members, volunteers, donors, sponsors, and thought leaders. It is because of this generous support – by people just like you – that PAA continues to fulfill and grow the promise of its mission to improve the lives of Parkinson’s patients, caregivers, and loved ones throughout Alabama. We hope you’ll consider a donation to the Parkinson Association of Alabama as part of your holiday giving plans. Every donation matters and plays a role in delivering the PD research and care programs that benefit those affected by Parkinson’s throughout the State.

Click here to donate online or contact Mary T if you’d like to send the gift of a PAA donation to a friend or loved one. For gift donations, we can send the lucky recipient a beautiful card on your behalf to notify them of your gift.

 

The post The Season of Giving appeared first on Parkinson Association of Alabama.

]]>
http://www.parkinsonalabama.com/the-season-of-giving-2018/feed/0
2018 Alabama Parkinson Fighter Walk & 5K: Event Recaphttp://www.parkinsonalabama.com/2018-alabama-parkinson-fighter-walk-5k-event-recap/ http://www.parkinsonalabama.com/2018-alabama-parkinson-fighter-walk-5k-event-recap/#respondSat, 27 Oct 2018 13:00:00 +0000http://www.parkinsonalabama.com/?p=3729607Thanks to the PAA Jr. Board and other volunteers, the 2018 Alabama Parkinson Fighter Walk & 5K was a huge success! This years event included 350 participants and raised over…CLICK TO READ MORE

The post 2018 Alabama Parkinson Fighter Walk & 5K: Event Recap appeared first on Parkinson Association of Alabama.

]]>
Thanks to the PAA Jr. Board and other volunteers, the 2018 Alabama Parkinson Fighter Walk & 5K was a huge success! This years event included 350 participants and raised over…CLICK TO READ MORE

The post 2018 Alabama Parkinson Fighter Walk & 5K: Event Recap appeared first on Parkinson Association of Alabama.

]]>
http://www.parkinsonalabama.com/2018-alabama-parkinson-fighter-walk-5k-event-recap/feed/0
MJFF and Blackfynn Collaborate on Parkinson’s Study to Discover Biomarkershttp://www.parkinsonalabama.com/mjff-and-blackfynn-collaborate-on-parkinsons-study-to-discover-biomarkers/ http://www.parkinsonalabama.com/mjff-and-blackfynn-collaborate-on-parkinsons-study-to-discover-biomarkers/#respondFri, 26 Oct 2018 13:27:00 +0000http://www.parkinsonalabama.com/?p=3729890The Michael J. Fox Foundation (MJFF) and Blackfynn are joining forces to make optimal use of an initiative that could uncover Parkinson’s disease biomarkers and bring about new therapies. Called the Parkinson’s Progression Markers Initiative (PPMI), the MJFF-backed effort is an ongoing observational study of more than 1,300 volunteer participants both with and without Parkinson’s […]

The post MJFF and Blackfynn Collaborate on Parkinson’s Study to Discover Biomarkers appeared first on Parkinson Association of Alabama.

]]>
MJFF and PPMI

The Michael J. Fox Foundation (MJFF) and Blackfynn are joining forces to make optimal use of an initiative that could uncover Parkinson’s disease biomarkers and bring about new therapies.

Called the Parkinson’s Progression Markers Initiative (PPMI), the MJFF-backed effort is an ongoing observational study of more than 1,300 volunteer participants both with and without Parkinson’s to validate biomarkers and, over time, identify disease risk factors. Participants undergo a battery of tests and assessments.

Biomarker discovery is critical in the quest for therapies that can slow or halt Parkinson’s progression. Specifically, it would allow for earlier diagnosis, better disease tracking, and more efficient therapy tests. Current treatments only temporarily ease symptoms.

To glean as much as possible from patient data, Blackfynn will lead the PPMI Advanced Analytics Core, established to analyze biomarker discovery. The firm has a data integration and analysis platform it uses to drive development of therapies, and advance translational research for neurological diseases.

“The goal of the Advanced Analytics Core is to accelerate our analysis of the comprehensive within-subject data collected through PPMI,” Kenneth Marek, PPMI principal investigator, said in a news release.

“By combining this rich, multimodal data with Blackfynn’s platform and data science expertise, we hope to uncover insights into the determinants of [Parkinson’s disease] progression that will lead to new therapies and improved quality of life for patients.”

The Blackfynn infrastructure incorporates a full complement of medical and scientific data to enable swift assessment of data correlations and complex data visualizations. PPMI scientists plan to use the platform to interpret data, develop verifiable hypotheses, and better collaborate with the goal of more targeted translational research.

“Our work with MJFF and the PPMI investigators will maximize the value of this important patient dataset and help drive novel discovery with the potential to lead to the development of effective therapies for patients with PD,” said Amanda Christini, president of Blackfynn.

“Blackfynn will enable a new lens through which discoveries can be made, by looking at all raw and metadata together, in context, to find new patterns that are otherwise obscured when data are in isolation.”

Citing an unwieldiness caused by an abundance of Parkinson’s-related biomarker information, an editorial in the journal The Lancet Neurology heralded the efficiencies of collaborative research. Particularly, it applauded the Accelerating Medicines Partnership for its efforts to find a Parkinson’s cure.

As for the PPMI, five-year results have already shown that clinical trials in patients with early-stage Parkinson’s may benefit from assessing markers of disease progression — namely, changes in the Movement Disorder Society (MDS)-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and dopamine transporter imaging.

Launched in 2010, PPMI is underway in the United States, Europe, Israel and Australia.

The MJFF is dedicated to finding a cure for Parkinson’s by funding research and ensuring the development of improved therapies for those living with the disease. It has funded more than $800 million in research to date.

The post MJFF and Blackfynn Collaborate on Parkinson’s Study to Discover Biomarkers appeared first on Parkinson’s News Today.

The post MJFF and Blackfynn Collaborate on Parkinson’s Study to Discover Biomarkers appeared first on Parkinson Association of Alabama.

]]>
http://www.parkinsonalabama.com/mjff-and-blackfynn-collaborate-on-parkinsons-study-to-discover-biomarkers/feed/0
2018 Parkinson’s Symposium Media Archivehttp://www.parkinsonalabama.com/2018-parkinsons-symposium-media-archive/ http://www.parkinsonalabama.com/2018-parkinsons-symposium-media-archive/#respondTue, 16 Oct 2018 04:57:00 +0000http://www.parkinsonalabama.com/?p=3729730Our annual symposium draws PD patients, caregivers, and loved ones from all over Alabama to engage multiple thought leaders who are experts in Parkinson’s Disease research, treatment, care and other focus areas. Whether you’re a PD patient, caregiver, medical professional, advocate, or simply want know more about this complex disease – the Parkinson’s Symposium offers something for everyone. This […]

The post 2018 Parkinson’s Symposium Media Archive appeared first on Parkinson Association of Alabama.

]]>
Our annual symposium draws PD patients, caregivers, and loved ones from all over Alabama to engage multiple thought leaders who are experts in Parkinson’s Disease research, treatment, care and other focus areas. Whether you’re a PD patient, caregiver, medical professionaladvocate, or simply want know more about this complex disease – the Parkinson’s Symposium offers something for everyone.

This years event was Saturday, September 15 from 8:30AM to 2:00 PM at The Club (Ballroom) in Birmingham.

If you were unable to attend the 2018 Parkinson’s Symposium, we hope you’ll take a moment to review our media archive – speaker presentation materials and audio along with a photo gallery of all attendees and participants.

CLICK TO REVIEW MEDIA ARCHIVE

The post 2018 Parkinson’s Symposium Media Archive appeared first on Parkinson Association of Alabama.

]]>
http://www.parkinsonalabama.com/2018-parkinsons-symposium-media-archive/feed/0
Parkinson’s Institute and Clinical Center, Retrotope Collaboration to Test RT001 in Progressive Supranuclear Palsyhttp://www.parkinsonalabama.com/parkinsons-institute-and-clinical-center-retrotope-collaboration-to-test-rt001-in-progressive-supranuclear-palsy/ http://www.parkinsonalabama.com/parkinsons-institute-and-clinical-center-retrotope-collaboration-to-test-rt001-in-progressive-supranuclear-palsy/#respondTue, 09 Oct 2018 13:03:00 +0000http://www.parkinsonalabama.com/parkinsons-institute-and-clinical-center-retrotope-collaboration-to-test-rt001-in-progressive-supranuclear-palsy/Parkinson’s Institute and Clinical Center and Retrotope have paired up to explore the therapeutic potential of the investigational agent RT001 in patients with progressive supranuclear palsy (PSP), a type of treatment-resistant Parkinson’s disease. Under Retrotope’s expanded access program for RT001, the institute’s physicians started dosing two PSP patients with the investigational therapy. This pilot study is […]

The post Parkinson’s Institute and Clinical Center, Retrotope Collaboration to Test RT001 in Progressive Supranuclear Palsy appeared first on Parkinson Association of Alabama.

]]>
Parkinson’s Institute and Clinical Center and Retrotope have paired up to explore the therapeutic potential of the investigational agent RT001 in patients with progressive supranuclear palsy (PSP), a type of treatment-resistant Parkinson’s disease.

Under Retrotope’s expanded access program for RT001, the institute’s physicians started dosing two PSP patients with the investigational therapy. This pilot study is expected to provide information to help guide future randomized placebo-controlled trials in PSP.

“The Parkinson’s Institute and Clinical Center brings novel therapies for [Parkinson’s disease] to patients in need,” Carrolee Barlow, MD, PhD and CEO of the institute, said in a press release. “We look forward to working with Retrotope in evaluating the responses to this therapeutic candidate in these patients.”
RT001 belongs to a new therapy class called deuterated polyunsaturated fatty acids, or D-PUFAs, that protect mitochondria and cells from damage caused by oxidation of fat molecules, which often results in cell death that is a hallmark of numerous neurodegenerative diseases including Parkinson’s. Mitochondria provide energy and are known as the “powerhouses” of the cells. The investigational agent is an engineered, more stable form of linoleic acid that mimics the protective effects of the fatty molecule Omega-6.

RT001 is integrated in cell and mitochondria membranes and, as it is a stabilized fatty molecule, does not react with damaging free reactive oxygen elements — toxic compounds produced as a consequence of cellular oxidative stress — restoring membrane function and cellular health.

“The patients we treat with these fatal, degenerative diseases are willing to try therapies which appear safe and for which there is a mechanistic rationale that they may benefit from the treatment,” Barlow said. “Retrotope is a willing partner with a highly unique and well-studied approach to addressing neurodegenerative diseases.”
“The institute’s goal is to find a cure for Parkinson’s and Expanded Access programs like Retrotope’s are really at the forefront of generating hope for patients from novel therapies, and data for pharmaceutical companies to plan their drug trials,” she added.

The therapeutic potential of this investigational agent is being tested in patients with inherited Friedreich’s ataxia (FA) and infantile neuroaxonal dystrophy (INAD).
In addition, this new agent has been shown in preclinical studies to hold therapeutic potential in other illnesses where mitochondria function and induced cell death play a role, including Alzheimer’s, Parkinson’s, Huntington’s, and amyotrophic lateral sclerosis (ALS).

Preclinical data has shown that RT001 orally administered to mice with induced Parkinson’s disease could effectively improve the levels of dopamine by 2.5 times in the brain area most affected by the disease. In addition, the treatment effectively prevented brain cells’ degeneration in these animals.“Early results in clinical trials of RT001 and Expanded Access programs for a variety of neurodegenerative diseases have generated encouraging results along with a favorable safety profile,” said Peter G. Milner, MD and chief medical officer of Retrotope. “We look forward to providing updates on this and other studies in the coming months as we support patients and investigators exploring the utility of RT001 to block lipid peroxidation in a range of primary neurodegenerative diseases.”

Source: Parkinson’s News Today

The post Parkinson’s Institute and Clinical Center, Retrotope Collaboration to Test RT001 in Progressive Supranuclear Palsy appeared first on Parkinson Association of Alabama.

]]>
http://www.parkinsonalabama.com/parkinsons-institute-and-clinical-center-retrotope-collaboration-to-test-rt001-in-progressive-supranuclear-palsy/feed/0